| 2026-05-18 09:06 |
8-K |
["1.02"] |
merger agreement |
1.00
|
Completed merger: Neurocrine acquired Soleno for $53/share via tender offer (88.9% tendered, effective 5/18/2026). |
SEC · detail |
| 2026-05-18 09:04 |
SC 14D9 |
|
tender offer |
1.00
|
Completed tender offer and merger: Neurocrine acquired Soleno at $53/share; 88.9% tendered; merger closed May 18, 2026. |
SEC · detail |
| 2026-05-18 08:57 |
SC TO-T |
|
tender offer |
1.00
|
Completed tender offer: Neurocrine acquired Soleno at $53/share, 88.9% tendered, merger consummated May 17, 2026. |
SEC · detail |
| 2026-04-29 16:31 |
SC TO-T |
|
tender offer |
0.99
|
Neurocrine Biosciences tender offer for Soleno Therapeutics at $53/share via third-party offer. |
SEC · detail |
| 2026-04-28 07:30 |
SC TO-T |
|
tender offer |
0.99
|
Neurocrine Biosciences conducting third-party tender offer for Soleno at $53/share; HSR clearance obtained as of April 27, 2026. |
SEC · detail |
| 2026-04-28 07:30 |
SC 14D9 |
|
tender offer |
0.98
|
Amendment to SC 14D-9 confirms Neurocrine's $53/share tender offer for Soleno; HSR approval obtained April 27, 2026. |
SEC · detail |